This type of Leishmaniasis affects both the skin and the lining of the nose, mouth, and throat. It starts with skin sores and can spread to these internal areas, causing problems like nosebleeds.
Every report comes from a Lived member, sent anonymously.
Have you tried Amphotericin B for Mucocutaneous Leishmaniasis?
Mucocutaneous leishmaniasis, also called mucosal leishmaniasis, is a parasitic infection that damages the moist lining (mucosa) of the nose, mouth and throat. It is a complication of cutaneous leishmaniasis, the more familiar form that causes long-lasting skin sores. In a small minority of people, the parasites spread from the skin to the nose and throat, where ongoing inflammation can slowly destroy tissue. The nose is usually affected first. Early signs are persistent, unexplained stuffiness, discharge or nosebleeds that don't behave like an ordinary cold or allergy. Sores, swelling or a hole in the wall between the nostrils (the septum) can follow. The mouth, palate, throat and voice box may become involved as the disease advances, and in some people these are the first places noticed. Mucosal disease typically appears months to years, sometimes decades, after a skin sore has healed, but it can also show up at the same time as skin sores or without any sore the person remembers. It matters because the damage builds over time. Left untreated, it can disfigure the nose and face, and involvement of the voice box can threaten breathing. Treatment can stop the infection, which is why recognizing it early makes a difference.
The parasites, called Leishmania, are spread by the bites of infected sand flies, tiny insects that bite mostly between dusk and dawn. The classic form of this disease comes from a few species found in Central and South America, especially Leishmania braziliensis. More than 90 percent of cases occur in Bolivia, Brazil, Ethiopia and Peru. It is very unlikely to be acquired in the United States, so cases there usually involve people who have lived in or traveled to affected regions. Most people with skin infection never develop mucosal disease; reviews estimate fewer than 5 percent do. In the Americas, the risk appears higher in men, in people whose skin sores were large, numerous or above the waist, in people whose skin infection went untreated or was incompletely treated, and in people who are malnourished. Inherited differences in immune response may also play a part. Adequate treatment of the original skin infection may reduce the risk but does not remove it entirely. A less common pattern occurs around the Mediterranean, including Spain, caused by a different species. There, mucosal disease often appears without any earlier skin sore and is seen more often in older adults with weakened immune systems, such as people with HIV or those taking steroids, transplant medicines or other immune-suppressing treatments.
A clinician starts with where the person has lived or traveled, whether they ever had a slow-healing skin sore or have a scar from one, and how their nose, mouth or throat symptoms have changed over time. Because the disease can look like other problems, including chronic sinus disease, other infections, autoimmune conditions and even cancer, confirming the parasite matters before treatment begins. An ear, nose and throat specialist examines the inside of the nose, throat and voice box, usually with a thin lighted scope (endoscopy). A small tissue sample (biopsy) is taken from any abnormal area. The laboratory looks for the parasite under the microscope, tries to grow it in culture and uses DNA tests such as PCR (polymerase chain reaction), the most sensitive method available. Identifying the exact species can help guide treatment. In the United States, specialized reference laboratories, including at the CDC (Centers for Disease Control and Prevention), help with this testing. Blood tests for antibodies are not reliable for diagnosing this form of leishmaniasis. Before treatment starts, the specialist maps how far the disease has spread, because the extent of involvement, particularly in the throat and voice box, affects both outlook and how treatment is given.
Everyone with mucosal leishmaniasis needs systemic treatment, meaning medicine that works throughout the body rather than on a single spot. The goals are to stop further tissue destruction and disfigurement and to prevent serious breathing complications. There is no single best drug, and the evidence comparing options is limited, so specialists individualize the choice based on the species, where the infection was acquired, the extent of disease, other health conditions and whether a medicine is available. The main options are: Pentavalent antimonials, the longest-used treatment, given by injection or infusion daily for about four weeks. They are widely used in Latin America but have only moderate cure rates and notable side effects. They are not commercially available in the United States and can be obtained only through a special investigational process run by the Food and Drug Administration (FDA). Amphotericin B, an antiparasitic and antifungal medicine given by intravenous infusion. The liposomal form is generally better tolerated than the older conventional form and is often used, though its evidence in mucosal disease comes mainly from case series. Miltefosine (Impavido), the only oral option, taken as capsules for 28 days. It is FDA-approved for mucosal leishmaniasis caused by Leishmania braziliensis in people 12 and older who weigh at least 30 kilograms (66 pounds), and its cure rate appears similar to antimonials. It can cause serious harm to a developing baby, so it is not used during pregnancy, and people who could become pregnant need a pregnancy test first and effective contraception during treatment and for 5 months afterward. When the throat or voice box is involved, treatment may begin in the hospital, sometimes with corticosteroids, because an inflammatory reaction after treatment begins can swell the airway. Treatment usually involves an infectious disease or tropical medicine specialist, who can also consult with the CDC.
Treatment is demanding. Most options involve weeks of injections or infusions, often with blood tests and other monitoring for side effects, and some people need a change of medicine because of side effects or an incomplete response. Cure rates are imperfect and the research guiding treatment is mostly low quality, so it is reasonable to expect close follow-up rather than a single fixed course. As the infection is controlled, inflammation, sores and nasal symptoms usually settle. The outlook depends heavily on how far the disease had spread before treatment; specialists consider more extensive disease, especially in the throat or voice box, more serious. Tissue changes to the nose or face can affect appearance, breathing through the nose, speech or swallowing, and these effects can weigh on daily life and self-confidence. Follow-up examinations of the nose and throat continue after treatment to confirm healing and catch any return of disease. Medicines may not clear every parasite from the body, so relapse is possible, and the risk rises if the immune system later becomes weakened, for example by HIV or immune-suppressing treatments. Telling future clinicians about the history helps them recognize a relapse.
See a clinician if you have nasal stuffiness, discharge or nosebleeds that persist without a clear cause, sores inside the nose or mouth, or a hoarse voice that won't go away, and you have ever had leishmaniasis, have a scar from a slow-healing skin sore, or have lived in or traveled to an area where it occurs. Mention the travel history directly, because these symptoms are easy to mistake for common problems. During or after treatment, contact the care team promptly if nose or throat symptoms worsen, new sores appear, swallowing becomes difficult or medicine side effects are troubling. Call 911 for noisy or labored breathing, severe difficulty breathing or choking, especially if the throat or voice box is known to be involved.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Mucocutaneous Leishmaniasis is like, what's helped you, or ask the community a question.